Compare ANL & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ANL | BDSX |
|---|---|---|
| Founded | 2004 | 2005 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | | Precision Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 350.9M | 122.0M |
| IPO Year | 2022 | 2020 |
| Metric | ANL | BDSX |
|---|---|---|
| Price | $8.00 | $14.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $16.00 | ★ $32.50 |
| AVG Volume (30 Days) | ★ 446.4K | 127.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $88,499,000.00 |
| Revenue This Year | N/A | $22.01 |
| Revenue Next Year | N/A | $26.81 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 24.08 |
| 52 Week Low | $0.88 | $0.25 |
| 52 Week High | $12.09 | $17.40 |
| Indicator | ANL | BDSX |
|---|---|---|
| Relative Strength Index (RSI) | 48.67 | 70.89 |
| Support Level | $1.36 | $6.33 |
| Resistance Level | $12.09 | N/A |
| Average True Range (ATR) | 0.81 | 1.66 |
| MACD | -0.52 | 0.28 |
| Stochastic Oscillator | 19.39 | 70.94 |
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.